Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

BA-BE Studies: SOP for Setting Up eTMF (Electronic Trial Master File) – V 2.0

Posted on By

BA-BE Studies: SOP for Setting Up eTMF (Electronic Trial Master File) – V 2.0

Standard Operating Procedure for Setting Up eTMF (Electronic Trial Master File) in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/042/2025
Supersedes SOP/BA-BE/042/2022
Page No. Page 1 of 13
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To define the procedure for establishing and maintaining an Electronic Trial Master File (eTMF) system for BA/BE studies, ensuring real-time documentation, compliance with ICH-GCP guidelines, and audit readiness.

2. Scope

This SOP applies to all BA/BE studies where an eTMF is implemented to manage essential documents throughout the study lifecycle including planning, conduct, and closeout phases.

3. Responsibilities

  • Clinical Document Manager: Leads the eTMF setup, configuration, and maintenance activities.
  • Clinical Project Manager (CPM): Ensures timely upload and completeness of study-specific documents.
  • Quality Assurance: Reviews eTMF structure and compliance during audits.
  • IT Department: Provides technical support for access control, data backup, and software validation.
See also  BA-BE Studies: SOP for Regulatory Submission Planning for BE Studies - V 2.0

4. Accountability

The Head of Clinical Operations is accountable for ensuring the eTMF system is implemented, validated, and maintained in compliance with regulatory standards and internal policies.

5. Procedure

5.1 Selection and Validation of eTMF System

  1. Select a validated eTMF platform with 21 CFR Part 11 compliance.
  2. Complete IT validation documentation including user requirement specifications (URS), functional specification (FS), and validation summary report.

5.2 Folder Structure and Metadata Setup

  1. Configure the folder structure as per the DIA Reference Model (Annexure-1: eTMF Folder Mapping).
  2. Assign document metadata fields such as:
    • Study ID
    • Country/Site
    • Document Type
    • Version
    • Date

5.3 User Access and Permissions

  1. Define user roles and access levels (e.g., Viewer, Editor, Approver).
  2. Maintain user list in Annexure-2: eTMF Access Log.
See also  BA-BE Studies: SOP for Registration of BE Trials on CTRI - V 2.0

5.4 Document Upload and QC

  1. Upload essential documents into the appropriate folders following standardized naming conventions.
  2. Each document must be reviewed and quality-checked before final approval.
  3. Track version history and archival status for every file.

5.5 Milestone Tracking and Completeness Check

  1. Configure milestone-based document tracking (e.g., Site Initiation, First Subject First Visit, Database Lock).
  2. Use Annexure-3: eTMF Completeness Checklist to monitor document availability for each milestone.

5.6 Archival and Closeout

  1. Post-study, lock the eTMF and generate audit trail report.
  2. Export eTMF to secure archival location with backup maintained for 15 years (or as per regional regulations).

6. Abbreviations

  • eTMF: Electronic Trial Master File
  • CPM: Clinical Project Manager
  • GCP: Good Clinical Practice
  • DIA: Drug Information Association
  • URS: User Requirement Specification

7. Documents

  1. eTMF Folder Mapping – Annexure-1
  2. eTMF Access Log – Annexure-2
  3. eTMF Completeness Checklist – Annexure-3

See also  BA-BE Studies: SOP for Blinding and Unblinding Protocols in BA/BE Studies - V 2.0

8. References

  • ICH E6(R2) – Good Clinical Practice
  • 21 CFR Part 11 – Electronic Records and Signatures
  • DIA TMF Reference Model

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: eTMF Folder Mapping

Section Folder Name Description
01 Trial Management Study plans, meeting minutes, Gantt charts
02 Central Trial Documents Protocol, IB, protocol amendments

Annexure-2: eTMF Access Log

User Name Role Access Level Date Activated Status
Rajesh Kumar CPM Editor 01/04/2025 Active

Annexure-3: eTMF Completeness Checklist

Milestone Document Type Available (Y/N) Remarks
Study Start-Up EC Approval Letter Y Uploaded on 12/04/2025

Revision History:

Revision Date Revision No. Details Reason Approved By
10/01/2022 1.0 Initial SOP eTMF process implementation QA Head
17/04/2025 2.0 Added DIA model alignment and Annexures Regulatory audit readiness QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: API Manufacturing: SOP for Pest Control and Monitoring Program – V 2.0
Next Post: Creams: SOP for Operating Tube-Filling Machines – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version